Document Detail

Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction.
MedLine Citation:
PMID:  12851535     Owner:  NLM     Status:  MEDLINE    
We describe a case where danaparoid was used prophylactically in a high-risk twin pregnancy following the development of heparin-allergy while on prophylactic dalteparin. Danaparoid was substituted for dalteparin at 20 weeks of pregnancy following the development of a severe skin reaction while on the low molecular weight heparin. Although there was no significant fall in platelet count, an aggregation assay for heparin-induced thrombocytopaenia was positive. The skin lesions rapidly resolved following the change to subcutaneous danaparoid. Delivery was by emergency caesarian section at 35 weeks under a general anaesthetic, as a dose of danaparoid had been given 6 h prior to delivery. A sample of breast milk showed no anti-activated factor X activity. Danaparoid was continued post-delivery until the patient was fully warfarinized. To our knowledge, there are no previous reports of the use of danaparoid in this setting.
Bethan Myers; John Westby; Jane Strong
Related Documents :
11704215 - Preclinical phase of polycythemia vera in pregnancy.
8513545 - Noninfectious respiratory disease in pregnancy.
25469525 - Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy out...
12128275 - The use of low-molecular-weight heparin for the management of venous thromboembolism in...
22295115 - Maternal use of antibiotics, hospitalisation for infection during pregnancy, and risk o...
25386425 - Electrocradiographic qrs axis, q wave and t-wave changes in 2nd and 3rd trimester of no...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  14     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-07-09     Completed Date:  2004-04-15     Revised Date:  2005-05-12    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  485-7     Citation Subset:  IM    
Department of Clinical Haematology, Queen's Medical Centre, University Hospital, Nottingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use*
Cesarean Section
Chondroitin Sulfates / therapeutic use*
Dermatan Sulfate / therapeutic use*
Drug Combinations
Drug Eruptions / etiology
Heparin / adverse effects
Heparitin Sulfate / therapeutic use*
Infant, Newborn
Injections, Subcutaneous
Platelet Count
Pregnancy Complications, Hematologic / prevention & control*
Pregnancy, High-Risk*
Pregnancy, Multiple
Puerperal Disorders / prevention & control
Pulmonary Embolism / prevention & control
Thrombocytopenia / etiology
Thrombosis / prevention & control*
Warfarin / administration & dosage,  therapeutic use
Reg. No./Substance:
0/Anticoagulants; 0/Drug Combinations; 24967-94-0/Dermatan Sulfate; 81-81-2/Warfarin; 83513-48-8/danaproid; 9005-49-6/Heparin; 9007-28-7/Chondroitin Sulfates; 9050-30-0/Heparitin Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Potential dosing errors using portable prothrombin time monitoring devices.
Next Document:  Deep vein thrombosis and acute cytomegalovirus infection: case report and review of the literature.